MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Mangoceuticals, Inc. (MGRX)
Company Research
Source: GlobeNewswire
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder’s equity and gross revenues. During the six months ending June 30, 2024, MangoRx’s shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial portion of this increase is attributed to the Company’s recent acquisition of the comprehensive global patent portfolio surrounding respiratory illness and preventive care technology from Intramont Technologies in April 2024, which is currently undergoing 3rd party efficacy studies anticipated to
Show less
Read more
Impact Snapshot
Event Time:
MGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGRX alerts
High impacting Mangoceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MGRX
News
- Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
- MangoRx Announces Formation of Strategy and Alternatives CommitteeGlobeNewswire
- MangoRx Responds to and Refutes Recent Claims Made by Eli LillyGlobeNewswire
- MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLANGlobeNewswire
- MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsGlobeNewswire
MGRX
Sec Filings
- 10/31/24 - Form 8-K
- 10/25/24 - Form 8-K
- 10/22/24 - Form 8-K
- MGRX's page on the SEC website